Before too long, it'll be the AGM and everyone can ask all the questions they want. I suspect the company is simply interested in the bigger and more profitable markets available through "off-the-shelf" products, than what any autologous based therapy will ever allow. MSB is geared toward becoming a "large" bio-pharma, not a specialist "personalised medicine" provider, our CEO has made that clear.
They MAY have once [perhaps seriously] toyed with the idea of "personalised" but realised their current generation MPC based treatments are much more suited toward "mass market" medicine.
I see no major negatives with MSB and simply encourage them to keep programs advancing.
Before too long, it'll be the AGM and everyone can ask all the...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.47 |
Change
-0.045(2.98%) |
Mkt cap ! $1.672B | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.50 | $1.45 | $8.307M | 5.669M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 151320 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 55652 | 2 |
View Market Depth
| Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |